Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Ear Hear. 2022 Jan 21;43(3):794–807. doi: 10.1097/AUD.0000000000001172

Table 8.

Final Multivariable Ordinal Logistic Regression Model of Factors Associated with Cisplatin-Associated ASHA-Defined Hearing Loss Severity

Variable OR (95% CI) P value
Age at audiometry 1.13 (1.12-1.15) <0.0001
Cumulative dose of cisplatin, mg/m2
 ≤ 300 Ref.
 > 300 1.47 (1.21-1.80) 0.0001
Education
 High school or less Ref.
 After high school but not college graduate 0.78 (0.53-1.14) 0.19
 College or university graduate 0.87 (0.61-1.24) 0.44
 Post-graduate 0.58 (0.40-0.85) 0.005
Physical activity (total MET-hours/week) quartiles
 Quartile 1 Ref.
 Quartile 2 0.74 (0.56-0.98) 0.04
 Quartile 3 1.05 (0.79-1.40) 0.73
 Quartile 4 0.88 (0.66-1.17) 0.36
Hypertension and on prescription medication
 No Ref.
 Yes 1.80 (1.28-2.52) 0.0007

Abbreviations: ASHA, American Speech-Language-Hearing Association criteria; CI, confidence interval; METs, metabolic equivalent task; OR, odds ratio; Ref., reference.

Note: The ORs and P values are from an adjusted ordinal logistic regression model that includes all variables listed in the table with ASHA-defined hearing loss severity based on frequencies of 4 kHz to 12 kHz as the outcome (dependent) variable. Hearing loss was defined following methods in Frisina et al (Frisina et al. 2016) using ASHA for frequencies of 4 to 12 kHz for which dose-response relationships with cumulative amount of cisplatin was shown (Frisina et al. 2016).

Audiometry assessments based on ASHA (4-12 kHz) criteria among a total of 1,410 participants were as follows: 333 (23.6%), 327 (23.2%), 201 (14.3%), 284 (20.1%), 237 (16.8%), and 28 (2.0%) had no hearing loss (HL), mild HL (20-40 dB), moderate HL (41-55 dB), moderately severe HL (56-70 dB), severe HL (71-90 dB), and profound HL (> 90 dB), respectively. The frequency of any degree of audiometric-defined HL in each age category are as follows: 152/304 (50%), 355/501 (70.9%), 317/347 (91.4%), and 253/258 (98.1%) for <30 years, 30-39 years, 40-49 years, and ≥50 years, respectively.

Variables with Omnibus (Wald chi-square from type 3 analysis of effects) P>0.1 have been removed from the final model in a backward deletion procedure. The Omnibus P values for variables listed in the table are: age at audiometry (P<0.0001), cumulative dose of cisplatin (P=0.0001), education (P=0.005), total METS-hours/week (quartiles) (P=0.06), and hypertension and on prescription medication (P=0.0007).

P values with boldface indicate significance of P<0.05.